Navigation Links
VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
Date:10/25/2007

BOSTON October 25, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a study which demonstrated that adults with Attention Deficit Hyperactivity Disorder (ADHD) experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE (lisdexamfetamine dimesylate), the first prodrug stimulant. Findings from this phase III pivotal trial were presented today at a national psychiatric meeting in Boston, Mass.

Adults with ADHD may experience significant impairments in their ability to focus, and organize and complete tasks, which could affect their work, family life and personal relationships, said Lenard A. Adler, M.D., lead researcher in this study and director of the Adult ADHD Program at New York University School of Medicine and author of Scattered Minds: Help and Hope for Adults with ADHD. The results of this study demonstrated that VYVANSE significantly improved the core symptoms of ADHD in adult study patients.

Results of Phase III Pivotal Trial

In this double-blind, placebo-controlled, four-week study with dose escalations in 414 adults aged 18 to 55 years, treatment with VYVANSE at all doses studied (30 mg, 50 mg, 70 mg) was significantly more effective than placebo and improvements were observed in the first week of the study.

All doses of VYVANSE showed significant improvements in the average change in ADHD Rating Scale (ADHD-RS-IV) scores, as measured from the studys start to end, the primary endpoint of this study. ADHD-RS-IV is a standardized, validated test for assessing symptoms of ADHD and for assessing their response to treatment. The scale, which contains 18 items, is based on the ADHD diagnostic criteria as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, a publication of the American Psychiatric Association.

VYVANSE provided a significant reduction in ADHD-RS-IV scores starting at week one that were observed throughout the full treatment period. At endpoint, VYVANSE provided a significant reduction in ADHD-RS-IV scores ranging from 16.2 to 18.6 points.

Investigators also measured the efficacy of VYVANSE with the Clinical Global Impressions-Improvement (CGI-I) scale, a standard assessment used to rate the severity of a patients illness and improvement over time. The study found that the percentage of subjects taking VYVANSE rated improved on the CGI-I scale ranged from 57 to 61 percent across all doses and was significantly greater than placebo.

The study showed there were no statistically significant differences among the groups for total score of Pittsburgh Sleep Quality Index (PSQI) at endpoint with all groups showing a slight decrease in the PSQI total score at endpoint. The PSQI is a self-rated questionnaire that assesses sleep quality and disturbances over a one-month time interval.

Adverse events reported in this study were generally mild to moderate and included dry mouth (26 percent), decreased appetite (27 percent) and insomnia (19 percent).

VYVANSE is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine. The pharmacokinetic profile of VYVANSE is inherent to its chemical prodrug nature and alterations in gastric pH and gastrointestinal motility do not affect its absorption.

A supplemental New Drug Application (sNDA) for VYVANSE for the treatment of ADHD in adults is currently under review by the U.S. Food and Drug Administration (FDA). VYVANSE is currently approved in the United States for the treatment of ADHD in children aged 6 to 12 years.


'/>"/>

Contact: Jacelyn Seng
212-601-8385
Porter Novelli
Source:Eurekalert

Related medicine news :

1. VYVANSE(TM) Drug for the Treatment of ADHD in Adults
2. Man against HIV – new vaccine ready for human trials
3. FDA approves Phase 0 trial which tests experimental drugs on humans
4. Male contraceptive in trial
5. How do patients benefit of clinical trials
6. Glenmark’s new molecule to go through trial
7. Clinical trials need to be more frank
8. First head-to-head trials of once weekly Fosamax and Actonel therapies
9. Hormone Replacement Therapy increases the risk of endometrial cancer
10. Atrial fibrillation predicts for acute ischaemic stroke
11. Spray on contraceptive clears Phase I trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... FL (PRWEB) , ... February 10, 2016 , ... AxoGen, ... market, will report results for the fourth quarter and full year ended December 31, ... host a conference call and webcast for the investment community following the release at ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact Phyllis Strupp ... book "Better with Age: The Ultimate Guide to Brain Training" by award-winning author ... The book’s publication date is March 16, 2016. A free review copy is ...
(Date:2/10/2016)... Beach, Florida (PRWEB) , ... February 10, 2016 ... ... Country Club) announced that it has been awarded the prestigious Distinguished Emerald Club ... World award program conducted by BoardRoom magazine, one of the most respected trade ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns combine the strength ... solution that ensures the integrity of biological samples while operating at ultra-high pressures ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... PITTSBURGH , 10 februari 2016 ... detta pressmeddelande får inte distribueras, vare sig ... inga anmälningssedlar kommer att accepteras från eller ... där Erbjudandet, distribution av detta pressmeddelande eller ... mot tillämpliga lagar eller regler eller skulle ...
(Date:2/10/2016)... , February 10, 2016 A new report from ... - states that the Alzheimer,s disease market will more than double from ... at a Compound Annual Growth Rate (CAGR) of 11%. Canada ... Italy , Spain , the UK, and ... during the forecast period. --> Canada , ...
(Date:2/10/2016)... , Feb. 10, 2016 Urologix, the ... the treatment of Benign Prostatic Hyperplasia (BPH), announces new ... Ash Keswani , a medical device industry veteran of ... the Limited Liability Company.  Plymouth, ... service lines, Cooled ThermoTherapy™ and Prostiva® RF Therapy, will ...
Breaking Medicine Technology: